Literature DB >> 24168191

Roles of epithelial-mesenchymal transition in cancer drug resistance.

Yulong Shang, Xiqiang Cai, Daiming Fan1.   

Abstract

Overcoming intrinsic and acquired drug resistance is a major challenge in treating cancer. Poor responses to drug treatment can result in metastasis, cancer dissemination and death. Recently, the epithelial-mesenchymal transition (EMT) has been found to play a critical role in cancer drug resistance, but the nature of this intrinsic link remains unclear. This review summarizes recent advances in the understanding of drug resistance and focuses especially on the association between EMT and drug resistance. We discuss the roles of EMT in regulating drug resistance across different types of cancer, focusing simultaneously on the molecular mechanisms and potential pathways involved in the regulation of drug resistance by EMT. In addition, we discuss potential therapeutic strategies to target EMT to reverse drug resistance.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24168191     DOI: 10.2174/15680096113136660097

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  48 in total

1.  Small molecule JQ1 promotes prostate cancer invasion via BET-independent inactivation of FOXA1.

Authors:  Leiming Wang; Mafei Xu; Chung-Yang Kao; Sophia Y Tsai; Ming-Jer Tsai
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

2.  Cathepsin L upregulation-induced EMT phenotype is associated with the acquisition of cisplatin or paclitaxel resistance in A549 cells.

Authors:  Mei-Ling Han; Yi-Fan Zhao; Cai-Hong Tan; Ya-Jie Xiong; Wen-Juan Wang; Feng Wu; Yao Fei; Long Wang; Zhong-Qin Liang
Journal:  Acta Pharmacol Sin       Date:  2016-11-14       Impact factor: 6.150

Review 3.  Microenvironmental regulation of therapeutic response in cancer.

Authors:  Florian Klemm; Johanna A Joyce
Journal:  Trends Cell Biol       Date:  2014-12-22       Impact factor: 20.808

4.  A miRNA-200c/cathepsin L feedback loop determines paclitaxel resistance in human lung cancer A549 cells in vitro through regulating epithelial-mesenchymal transition.

Authors:  Yi-Fan Zhao; Mei-Ling Han; Ya-Jie Xiong; Long Wang; Yao Fei; Xiao Shen; Ying Zhu; Zhong-Qin Liang
Journal:  Acta Pharmacol Sin       Date:  2017-12-07       Impact factor: 6.150

5.  Dysregulation of miR-200 family microRNAs and epithelial-mesenchymal transition markers in oral squamous cell carcinoma.

Authors:  Ganesan Arunkumar; Arunagiri Kuha Deva Magendhra Rao; Mayakannan Manikandan; Harikrishnan Prasanna Srinivasa Rao; Shanmugam Subbiah; Ramachandran Ilangovan; Avaniyapuram Kannan Murugan; Arasambattu Kannan Munirajan
Journal:  Oncol Lett       Date:  2017-10-31       Impact factor: 2.967

Review 6.  Roles and epigenetic regulation of epithelial-mesenchymal transition and its transcription factors in cancer initiation and progression.

Authors:  Jeong-Yeon Lee; Gu Kong
Journal:  Cell Mol Life Sci       Date:  2016-07-26       Impact factor: 9.261

7.  Pleckstrin homology-like domain, family A, member 1 (PHLDA1) and cancer.

Authors:  Maria Aparecida Nagai
Journal:  Biomed Rep       Date:  2016-01-25

8.  Y-box binding protein 1 (YB-1) promotes gefitinib resistance in lung adenocarcinoma cells by activating AKT signaling and epithelial-mesenchymal transition through targeting major vault protein (MVP).

Authors:  Lei Lou; Juan Wang; Fengzhu Lv; Guohui Wang; Yuehong Li; Lingxiao Xing; Haitao Shen; Xianghong Zhang
Journal:  Cell Oncol (Dordr)       Date:  2020-09-07       Impact factor: 6.730

9.  HMGA2 promotes breast cancer metastasis by modulating Hippo-YAP signaling pathway.

Authors:  Jianxin Xu; Xuejiao Fang; Luye Long; Sixuan Wang; Shihan Qian; Jianxin Lyu
Journal:  Cancer Biol Ther       Date:  2020-12-13       Impact factor: 4.742

Review 10.  Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma.

Authors:  Zhi Zeng; Qiliang Lu; Yang Liu; Junjun Zhao; Qian Zhang; Linjun Hu; Zhan Shi; Yifeng Tu; Zunqiang Xiao; Qiuran Xu; Dongsheng Huang
Journal:  Front Oncol       Date:  2021-07-07       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.